While KRAS mutations are the most well-known and evidence-based driver mutations in PDA, no driver mutation or predictive marker has been identified in IPMC, especially for determining prognosis or whether to perform surgical resection. The gene discussed is KRAS; the disease is Patent ductus arteriosus.